$46.7
Insights on Simulations Plus, Inc.
Revenue is up for the last 2 quarters, 14.5M → 18.30M (in $), with an average increase of 20.8% per quarter
Netprofit is up for the last 3 quarters, 534.0K → 4.02M (in $), with an average increase of 62.1% per quarter
In the last 1 year, Healthequity Inc has given 43.5% return, outperforming this stock by 29.2%
In the last 3 years, Healthequity Inc has given 6.7% return, outperforming this stock by 21.9%
0.29%
Downside
Day's Volatility :1.89%
Upside
1.6%
30.41%
Downside
52 Weeks Volatility :37.74%
Upside
10.54%
Period | Simulations Plus, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 24.6% | -1.1% | 0.0% |
6 Months | 29.26% | 10.5% | 0.0% |
1 Year | 14.29% | 5.4% | 0.5% |
3 Years | -15.25% | 14.4% | -21.1% |
Market Capitalization | 932.3M |
Book Value | $8.86 |
Dividend Share | 0.24 |
Dividend Yield | 0.51% |
Earnings Per Share (EPS) | 0.52 |
PE Ratio | 89.71 |
PEG Ratio | 9.77 |
Wall Street Target Price | 53.67 |
Profit Margin | 16.26% |
Operating Margin TTM | 24.27% |
Return On Assets TTM | 4.43% |
Return On Equity TTM | 6.16% |
Revenue TTM | 64.7M |
Revenue Per Share TTM | 3.24 |
Quarterly Revenue Growth YOY | 16.2% |
Gross Profit TTM | 43.1M |
EBITDA | 15.7M |
Diluted Eps TTM | 0.52 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.66 |
EPS Estimate Next Year | 0.8 |
EPS Estimate Current Quarter | 0.19 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 14.93%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 29.7M | ↑ 22.9% |
Net Income | 8.9M | ↑ 54.38% |
Net Profit Margin | 30.12% | ↑ 6.14% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 34.0M | ↑ 14.51% |
Net Income | 8.6M | ↓ 3.93% |
Net Profit Margin | 25.27% | ↓ 4.85% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 41.6M | ↑ 22.43% |
Net Income | 9.3M | ↑ 8.72% |
Net Profit Margin | 22.44% | ↓ 2.83% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 46.5M | ↑ 11.73% |
Net Income | 9.8M | ↑ 4.82% |
Net Profit Margin | 21.05% | ↓ 1.39% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 53.9M | ↑ 16.01% |
Net Income | 12.5M | ↑ 27.61% |
Net Profit Margin | 23.16% | ↑ 2.11% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 59.6M | ↑ 10.52% |
Net Income | 10.0M | ↓ 20.2% |
Net Profit Margin | 16.72% | ↓ 6.44% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 12.0M | ↑ 1.96% |
Net Income | 1.2M | ↑ 29.55% |
Net Profit Margin | 10.41% | ↑ 2.22% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 15.8M | ↑ 31.64% |
Net Income | 4.2M | ↑ 235.26% |
Net Profit Margin | 26.5% | ↑ 16.09% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 16.2M | ↑ 3.07% |
Net Income | 4.0M | ↓ 3.98% |
Net Profit Margin | 24.69% | ↓ 1.81% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 15.6M | ↓ 3.73% |
Net Income | 534.0K | ↓ 86.68% |
Net Profit Margin | 3.42% | ↓ 21.27% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 14.5M | ↓ 7.22% |
Net Income | 1.9M | ↑ 264.23% |
Net Profit Margin | 13.41% | ↑ 9.99% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 18.3M | ↑ 26.24% |
Net Income | 4.0M | ↑ 107.15% |
Net Profit Margin | 22.01% | ↑ 8.6% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 43.3M | ↑ 12.38% |
Total Liabilities | 11.4M | ↓ 10.63% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 45.2M | ↑ 4.43% |
Total Liabilities | 7.5M | ↓ 33.82% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 168.4M | ↑ 272.64% |
Total Liabilities | 12.4M | ↑ 64.81% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 180.0M | ↑ 6.86% |
Total Liabilities | 14.2M | ↑ 14.62% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 188.4M | ↑ 4.67% |
Total Liabilities | 10.1M | ↓ 28.61% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 186.1M | ↓ 1.21% |
Total Liabilities | 16.1M | ↑ 58.59% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 190.5M | ↑ 1.1% |
Total Liabilities | 10.3M | ↑ 2.02% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 173.2M | ↓ 9.06% |
Total Liabilities | 8.6M | ↓ 16.74% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 179.1M | ↑ 3.43% |
Total Liabilities | 9.7M | ↑ 13.2% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 186.1M | ↑ 3.89% |
Total Liabilities | 16.1M | ↑ 64.94% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 185.8M | ↓ 0.17% |
Total Liabilities | 13.4M | ↓ 16.39% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 194.0M | ↑ 4.41% |
Total Liabilities | 16.9M | ↑ 26.03% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 9.3M | ↑ 35.03% |
Investing Cash Flow | -2.3M | ↓ 46.53% |
Financing Cash Flow | -3.8M | ↓ 12.99% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 11.6M | ↑ 25.32% |
Investing Cash Flow | -2.0M | ↓ 16.02% |
Financing Cash Flow | -7.6M | ↑ 102.67% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 10.9M | ↓ 6.24% |
Investing Cash Flow | -75.5M | ↑ 3760.72% |
Financing Cash Flow | 102.4M | ↓ 1438.48% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 19.2M | ↑ 75.98% |
Investing Cash Flow | -26.7M | ↓ 64.58% |
Financing Cash Flow | -4.7M | ↓ 104.58% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 17.9M | ↓ 6.79% |
Investing Cash Flow | 4.3M | ↓ 116.1% |
Financing Cash Flow | -7.6M | ↑ 62.72% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 4.7M | ↓ 40.62% |
Investing Cash Flow | -6.4M | ↓ 378.85% |
Financing Cash Flow | -460.0K | ↓ 54.72% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 5.5M | ↑ 17.72% |
Investing Cash Flow | 5.3M | ↓ 183.29% |
Financing Cash Flow | -21.0M | ↑ 4463.04% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 8.5M | ↑ 54.27% |
Investing Cash Flow | 7.9M | ↑ 48.05% |
Financing Cash Flow | -628.0K | ↓ 97.01% |
Sell
Neutral
Buy
Simulations Plus, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Simulations Plus, Inc. | -2.1% | 29.26% | 14.29% | -15.25% | 101.64% |
Solventum Corp | -7.72% | -6.44% | -6.44% | -6.44% | -6.44% |
Veeva Systems Inc. | -5.25% | 3.72% | 13.6% | -21.86% | 42.33% |
Ge Healthcare Technologies Inc. | -10.17% | 11.79% | 0.61% | 31.38% | 31.38% |
Healthequity Inc | -1.06% | 16.91% | 43.47% | 6.74% | 11.74% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Simulations Plus, Inc. | 89.71 | 89.71 | 9.77 | 0.66 | 0.06 | 0.04 | 0.01 | 8.86 |
Solventum Corp | NA | NA | NA | 0.0 | 0.12 | 0.08 | NA | NA |
Veeva Systems Inc. | 62.08 | 62.08 | 1.35 | 4.76 | 0.13 | 0.05 | NA | 28.8 |
Ge Healthcare Technologies Inc. | 28.54 | 28.54 | 20.11 | 4.3 | 0.19 | 0.06 | 0.0 | 15.67 |
Healthequity Inc | 123.75 | 123.75 | 2.29 | 2.19 | 0.03 | 0.03 | NA | 23.63 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Simulations Plus, Inc. | Buy | $932.3M | 101.64% | 89.71 | 16.26% |
Solventum Corp | NA | $11.7B | -6.44% | NA | 16.42% |
Veeva Systems Inc. | Buy | $32.4B | 42.33% | 62.08 | 22.24% |
Ge Healthcare Technologies Inc. | Buy | $39.6B | 31.38% | 28.54 | 8.02% |
Healthequity Inc | Buy | $6.8B | 11.74% | 123.75 | 5.57% |
BlackRock Inc
Conestoga Capital Advisors, LLC
Neuberger Berman Group LLC
Vanguard Group Inc
Ranger Investment Management LP
State Street Corporation
In the quarter ending March,2024. Simulations Plus, Inc. has declared dividend of $0.06
Read Moresimulations plus, inc. (nasdaq: slp) is the premier developer of modeling & simulation software and consulting services supporting drug discovery, development research and regulatory submissions. we partner with companies to provide a data-driven, ‘strategic modeling methodology’, starting in early discovery, continuing through preclinical/clinical development, and concluding with clinical trials/post approval. with our subsidiaries, cognigen corporation and dilisym services, we offer #1-ranked, easy-to-use software (gastroplus™, admet predictor™, kiwi™, dilisym®, nafldsym®, pkplus™, and more) to bridge data mining, compound library screening with qsar models, pbpk/tk modeling & simulation in animals and humans following administration around the body, and quantitative systems pharmacology approaches. simulations plus technology is licensed to and used by regulatory agencies worldwide. for over 20 years, simulations plus has partnered with our clients to reduce costs and accelerate res
Organization | Simulations Plus, Inc. |
Employees | 192 |
CEO | Dr. Walter S. Woltosz M.A.S., M.S. |
Industry | Technology Services |